SCHEMBL5458151

SCHEMBL5458151

CN1CCc2cc(N(C)C)c(S(=O)(=O)c3ccc(Cc4cccc(Cl)c4)cc3)cc2CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.43
SIGMAR1 Q99720 1/20 0.42
HTR6 P50406 5/20 0.40
CYP3A4 P08684 2/20 0.40
HTR2A P28223 3/20 0.39
HTR2C P28335 3/20 0.39
USP2 O75604 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 3/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 1/20 0.36
RORC P51449 1/20 0.36
PGR P06401 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 2/20 0.35
TSHR P16473 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HSD11B1 P28845 1/20 0.35
DRD2 P14416 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5452896 0.91 HTR2C (0.42) SIGMAR1HTR6CYP3A4HTR2AHTR2C
SCHEMBL14411990 0.89 HTR6 (0.43) LTA4HHTR6CYP3A4HTR2AHTR2C
SCHEMBL5455402 0.89 HRH3 (0.38) HTR6CYP3A4HTR2AHTR2CUSP2
SCHEMBL5466786 0.88 SIGMAR1 (0.42) SIGMAR1HTR6HTR2AHTR2CUSP2
SCHEMBL5459725 0.88 SIGMAR1 (0.42) SIGMAR1CYP3A4USP2SMN1; SMN2LMNA
SCHEMBL5449041 0.87 DRD2 (0.43) HTR6CYP3A4HTR2AHTR2CUSP2
SCHEMBL5448126 0.86 LTA4H (0.47) LTA4HSIGMAR1USP2ALDH1A1GAA
SCHEMBL5458495 0.86 USP2 (0.36) HTR6CYP3A4HTR2AHTR2CUSP2
SCHEMBL5448741 0.85 USP2 (0.39) LTA4HHTR6CYP3A4HTR2AHTR2C
SCHEMBL5451428 0.85 GALR3 (0.42) HTR6HTR2AHTR2CUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP claimed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 LTA4H 3983/4885SIGMAR1 55/4885HTR6 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.